Synairgen plc (LON:SNG – Get Free Report) shares traded down 18.1% on Thursday . The stock traded as low as GBX 2.21 ($0.03) and last traded at GBX 2.21 ($0.03). 319,444 shares traded hands during trading, a decline of 7% from the average session volume of 342,987 shares. The stock had previously closed at GBX 2.70 ($0.03).
Synairgen Price Performance
The firm has a market cap of £4.53 million, a PE ratio of -75.00 and a beta of -2.23. The stock has a 50 day simple moving average of GBX 4.03 and a two-hundred day simple moving average of GBX 4.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77.
About Synairgen
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Recommended Stories
- Five stocks we like better than Synairgen
- How to Effectively Use the MarketBeat Ratings Screener
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- ETF Screener: Uses and Step-by-Step Guide
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Comparing and Trading High PE Ratio Stocks
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.